linjc16/ctgov huggingface dataset:
Patient Satisfaction After Patient-specific Jawline Augmentation

Study Overview
=================
Brief Summary
-----------------
The survey studies patient satisfaction after titanium patient specific jawline augmentation in congenital, post-trauma, deformity and transgender/cosmetic jaw angle/border deficiencies.

Detailed Description
-----------------
Additively manufactured titanium implants have been pre-designed in the hospital department, further designed and manufactured by 2 Belgian companies. The issue is if all patients have satisfactory perception of the improvement of their morphology and the actual outcome of the procedure, and how theur social ineractions are perceived today.

Official Title
-----------------
Patient Satisfaction After Patient-specific Jawline Augmentation

Conditions
-----------------
Congenital Deformity of Face, Post-traumatic Deformity

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All lower jaw augmentation implants Exclusion Criteria: - N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| survey<br> | Other: survey<br>* Face-Q conversion table<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction/Quality of Life | By means of 4 surveys (social, psychological, outcome and satisfaction) based on FACE-Q. The scales can be used independently of the other scales.Higher scores reflect a better outcome. If missing data is less than 50% of the scale's items, insert the mean of the completed items. Use the Conversion Table to convert the raw summed scale score into a score from 0 (worst) to 100 (best). | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Satisfaction, Jawline augmentation, Transgender, Cosmetic jaw angle
Tokushima Night Guard for Recurrent Aphthous Stomatitis

Study Overview
=================
Brief Summary
-----------------
The investigators will investigate whether the night guard can suppress the development of recurrent aphthous stomatitis (RAS). The investigators will record the patients' oral condition for 60 days before and after intervention with the night guard made of Ethylene-Vinyl Acetate copolymer (EVA). The patients' saliva will be analyzed for measurement of inflammatory cytokines or oxidative stress.

Detailed Description
-----------------
The study involved 20 patients (8 male and 12 female) with RAS. These patients suffered from RAS at least once a month. The investigators will record their oral condition for 60 days before and after intervention with the night guard made of EVA. Their saliva will be analyzed for further studies including measurement of inflammatory cytokines or oxidative stress.

Official Title
-----------------
Effects of a Night Guard on Aphthous Stomatitis

Conditions
-----------------
Aphthous Stomatitis

Intervention / Treatment
-----------------
* Device: night guard
* Device: placebo night guard


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients suffered from recurrent aphthous stomatitis at least once a month Exclusion Criteria: People do not have a experience of recurrent aphthous stomatitis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Night guard<br>the night guard made of EVA | Device: night guard<br>* 60 days before and after intervention with the night guard<br>|
| Placebo Comparator: Placebo night guard<br>Placebo night guard made of EVA | Device: placebo night guard<br>* 60 days before and after intervention with the placebo night guard<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of developed aphthous stomatitis |  | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| days until healing |  | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aphthous stomatitis, night guard, inflammatory cytokine
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.

Detailed Description
-----------------
The duration of treatment is 6 years.

Official Title
-----------------
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: rofecoxib
* Drug: Comparator: placebo (unspecified)


Participation Criteria
=================
Eligibility Criteria
-----------------
Regular PSA testing and study biopsies required.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: rofecoxib|nan|
|Drug: Comparator: placebo (unspecified)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to prostate cancer |  | Duration of Treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to aggressive prostate cancer |  | Duration of Treatment |
To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel

Study Overview
=================
Brief Summary
-----------------
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study

Detailed Description
-----------------
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, comparing AZELAIC ACID TOPICAL GEL 15% TO FINACEA® and both active treatments to a Placebo Control in the treatment of Moderate of Facial Rosacea.

Official Title
-----------------
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azeliac Acid Gel and Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea.

Conditions
-----------------
Rosacea

Intervention / Treatment
-----------------
* Drug: Azelaic Acid 15% topical gel
* Drug: Finacea® (azelaic acid) Gel, 15%
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or non-pregnant female ≥ 18 years-of-age with a clinical diagnosis of moderate facial rosacea; Subjects had to have a definite clinical diagnosis of facial rosacea severity Grade 3 as per the IGE Exclusion Criteria: Female subjects who were pregnant, nursing, or planning to become pregnant during study participation;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Subjects in this randomized, double-blind, placebo controlled, parallel-group, multiple-center study will be randomly assigned in a 2:2:1 ratio to treatment with the test product, reference product or placebo control, respectively
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Azelaic Acid 15% topical gel<br>Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face | Drug: Azelaic Acid 15% topical gel<br>* Gel<br>* Other names: Azelaic Acid;|
| Active Comparator: Finacea® (azelaic acid) Gel, 15%<br>Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face | Drug: Finacea® (azelaic acid) Gel, 15%<br>* Gel<br>* Other names: Azelaic Acid;|
| Placebo Comparator: Placebo<br>Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face | Drug: Placebo<br>* Gel<br>* Other names: Vehicle;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in inflammatory lesion counts | Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts | 12 weeks |
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
The muscarinic antagonist tolterodine is widely used treat urinary urge incontinence. Though acteylcholine is the primary excitatory neurotransmitter in the gastrointestinal tract, the phase III trials suggest that tolterodine infrequently causes constipation. Therefore, the objectives of this study are to assess if tolterodine affects the speed at which food travels through the stomach, intestines and colon (i.e., gastrointestinal and colonic transit) in healthy subjects.

Detailed Description
-----------------
The specific aims of this study are to test the hypotheses that the non-specific muscarinic antagonist tolterodine will not:- i) delay colonic transit and the proximal colonic emptying rate; ii) delay gastric emptying; nor iii) delay small intestinal transit compared to placebo in healthy subjects.

Official Title
-----------------
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects

Conditions
-----------------
Health

Intervention / Treatment
-----------------
* Drug: Tolterodine


Participation Criteria
=================
Eligibility Criteria
-----------------
Age 18-70 years old. Absence of gastrointestinal symptoms as characterized by bowel symptoms questionnaire and absence of significant anxiety or depression characterized by a hospital anxiety and depression questionnaire. Able to understand and willing to sign informed consent. Females who are nonpregnant, nonlactating, and willing to use a clinically approved methods of contraception two weeks prior to Day 0 until 1 week after the last dose of study medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tolterodine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colonic transit (as measured by GC24) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colonic transit (GC48) |  |  | 
| Ascending colon emptying t1/2 |  |  | 
| Colonic filling at 6 hours, i.e. a surrogate marker of small bowel transit time |  |  | 
| Gastric emptying time (1, 2, 4 hours, thalf) |  |  | 
| Average number of stools per day before and during treatment |  |  |
Disability and Self-rated Health Following Primary Knee Replacement

Study Overview
=================
Brief Summary
-----------------
Knee replacement is an effective treatment in late-stage osteoarthritis. It reduces pain and improves quality of life. There is, however, limited data concerning its results in older people and on its effect on how patients survive in regular activities of daily living (ADL), such as bathing and shopping. In this study, the results of knee replacement are evaluated from the point of view of disability in everyday activities and self-rated health. Moreover, association with ADL performance and clinical knee scores and severity of osteoarthritis are assessed.

Detailed Description
-----------------
This is a cross-sectional study with a 12 month follow-up for recruited patients. Most data are gathered by a postal questionnaire.

Official Title
-----------------
The Effects of Primary Knee Replacement for Osteoarthritis on Disability in Activities of Daily Living and Self-rated Health in Older People

Conditions
-----------------
Osteoarthritis, Knee Replacement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 75 years or more at the time of operation diagnosis of knee osteoarthritis scheduled for or operated on with primary knee replacement Exclusion Criteria: died during the follow-up inflammatory arthritides

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Knee replacement recipients<br>Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disability in activities of daily living |  | Baseline (recruitment) and at 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall self-rated health |  | Baseline (recruitment) and at 12 months | 
| Health-related quality of life (WOMAC) | For patients recruited in 2011-2012. | Baseline and 12 months postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
knee replacement, disability, older people
Detection of Early Idiopathic Pulmonary Fibrosis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Official Title
-----------------
The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF

Conditions
-----------------
Idiopathic Pulmonary Fibrosis

Intervention / Treatment
-----------------
* Other: blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Control Subjects: Subjects ≥ 18 y.o. No lung diseases Inclusion Criteria for IPF Patients: Informed consent Subjects ≥ 40 y.o. Naive patients with no IPF treatment IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria Inclusion Criteria for non-IPF ILD Patients: Informed consent Subjects ≥ 18 y.o. ILD diagnosis Exclusion Criteria for control subjects, IPF and non-IPF ILD patients: HIV Hepatitis B Hepatitis C Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>No lung diseases | Other: blood samples<br>* Blood samples<br>|
| Non-IPF ILD<br>non-IPF ILD diagnosis | Other: blood samples<br>* Blood samples<br>|
| IPF<br>Naive patients with no IPF treatment | Other: blood samples<br>* Blood samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine miR200 levels (fold change) in blood samples. | MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF. | Baseline (one time). |
A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program

Study Overview
=================
Brief Summary
-----------------
The objective of the trial is to assess the impact of a disinfection and hand hygiene program on absenteeism in elementary school classrooms. Students in intervention classrooms will use alcohol-based hand sanitizers at school, and their classrooms will be disinfected using quaternary ammonium wipes. We hypothesize that the use of disinfectants and hand hygiene products in elementary school classrooms will reduce absenteeism.

Official Title
-----------------
A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program

Conditions
-----------------
Respiratory Infections, Gastrointestinal Diseases

Intervention / Treatment
-----------------
* Other: Alcohol-based hand sanitizer & quaternary ammonium wipes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Member of a designated elementary school classroom in the Avon school system
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes. | Other: Alcohol-based hand sanitizer & quaternary ammonium wipes<br> <br> |
| No Intervention: 2<br>No hand sanitizer or disinfecting wipes were used. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absenteeism rate due to gastrointestinal or respiratory illness during the study period. |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial colony counts and the presence of selected viruses on classroom surfaces. |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of gastrointestinal and respiratory illness
The Effects of Continuous Passive Motion on Hypertonia of Soleus in Individuals With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
Cerebral palsy (CP) is a group of disorders of the development of movement and posture but often changing motor impairment syndromes. The spastic subtypes are the most common manifestations of cerebral palsy who perform movement difficultly due to hypertonia. Decease of spinal cord pathway, hyperactivity of alpha and gamma motoneuron and reduction of presynaptic inhibition may cause tendon reflex increase and hypertonia in individuals with CP. There are many ways to improve the hypertonia. In the past studies, the fast repeated range of motion could reduce muscle's activation effectively. The polyarticular movement training might increase joint range of motion and reduce the muscle activation. But the polyarticular movement training is difficulty for some individuals with CP. The single joint movement training may achieve the same effect as the polyarticular movement training. The purpose of this study was to investigate the effects of continuation passive range of motion (CPM) training whether could get the improvement of soleus hypertonia in individuals with CP.

Conditions
-----------------
Cerebral Palsy (CP)

Intervention / Treatment
-----------------
* Procedure: Ankle continuous passive motion machine.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Spastic CP Modified Ashworth scale of Soleus > 1 Ankle range of motion > 10 degrees Exclusion Criteria: Fracture on lower Lower extremities BOTOX on ankle < 5 mouths

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Spastic CP<br>continuous passive motion training | Procedure: Ankle continuous passive motion machine.<br>* A rehabilitation program of machine driven passive stretch.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle tone tests | Measure of changes in Hypertonia measured by Modified Ashworth Scale (MAS). | Baseline, 1, and 4 months. | 
| Ankle range of motion | Measure of changes in Ankle range of motion. | Baseline, 1, and 4 months. | 
| Hoffman reflex (H-reflex) | Measure of changes in Hoffman reflex (H-reflex). | Baseline, 1, and 4 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leg girth |  | Baseline,1 ,and 4 mouths. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral palsy, Continuous passive motion, Hypertonia